title: Does heparin coating improve biocompatibility? A study on complement, blood cells and postoperative morbidity during cardiac surgery.
abstract: To evaluate whether the effect of heparin coating the extracorporeal circuit resulted in differences in patient outcome and haemostatic alteration, 24 patients undergoing elective, isolated coronary artery bypass were randomized prospectively to cardiopulmonary bypass (CPB) with heparin-coated circuits (group H, n = 12) or uncoated circuits (group C, n = 12). The technique of CPB, heparinization and its reversal were the same in both groups. We studied complement status (C3d, C3, C3d/C3, C4 and C-function), white blood cell counts with differentiation and the postoperative morbidity. The results confirmed that CPB activates complement and increases neutrophils in both the H and C groups. A significantly lower level of leucocytosis was seen in group H compared to the C group (p < 0.05). The complement function via the classical pathway (C-function), expressed as a percentage of the function of a reference serum pool (the values of normal sera were 75-125%), was significantly reduced in both heparin-coated and uncoated circuits (p < 0.05). There was no significant intergroup difference regarding C3, C3d/C3, C4 and C-function during the study period. A lower frequency of postoperative morbidity was present in the H group. We conclude that heparin-coated surfaces elicit less leucocytosis and decrease postoperative morbidity in patients undergoing cardiac surgery but do not cause a significant difference regarding activation of the complement system as reported by many other investigators.
authors.affiliation: Department of Thoracic and Cardiovascular Surgery, University of Gothenbourg, Sahlgrenska Hospital, Sweden.
authors.forename: A
authors.initials: A
authors.lastname: Belboul
authors.forename: N
authors.initials: N
authors.lastname: al-Khaja
mesh_terms: D000925:Anticoagulants / Q000494:pharmacology*; D001672:Biocompatible Materials / Q000009:adverse effects*; D002315:Cardiopulmonary Bypass; D003167:Complement Activation; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D007958:Leukocyte Count; D011446:Prospective Studies
chemical_list: D000925:Anticoagulants; D001672:Biocompatible Materials; D006493:Heparin